Syros Pharmaceuticals, Inc. SYRS 10-K 2016 : FY   0001558370-17-001938

Annual report ( Financial statements and condition ) ( Risk ) ( Corporate Governance ) ( Executive compensation ) ( Management Discussion Analysis MDA MD&A )

filing date
March 20, 2017
period ending
Dec. 31, 2016
date of filing date change
March 20, 2017
Fiscal Period ends
2016-12-31
Fiscal year ends
--12-31
accession number
0001558370-17-001938
type
10-K
public document count
106
Financials (experimental)
In USD 3 mo ending 2016-12-31 3 mo ending 2015-12-31 12 mo ending 2016-12-31 12 mo ending 2015-12-31 12 mo ending 2014-12-31
Revenues  317,000    317,000  317,000  
Net Income  -10,965,000  -10,689,000  -47,743,000  -29,818,000  -13,431,000
EPS Diluted  -0.47  -5.14  -4.05  -17.55  -10.26
EPS Basic  -0.47  -5.14  -4.05  -17.55  -10.26
Tables, footnotes, etc (auto generated)
Link: Id filename
Document and Entity Information 35 R1.htm
CONSOLIDATED BALANCE SHEETS 36 R2.htm
CONSOLIDATED BALANCE SHEETS (Parenthetical) 37 R3.htm
CONSOLIDATED STATEMENTS OF OPERATIONS 38 R4.htm
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS 39 R5.htm
CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ (DEFICIT) EQUITY 40 R6.htm
CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ (DEFICIT) EQUITY (Parenthetical) 41 R7.htm
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS 42 R8.htm
Nature of Business 43 R9.htm
Summary of Significant Accounting Policies 44 R10.htm
Cash Equivalents and Marketable Securities 45 R11.htm
Fair Value Measurements 46 R12.htm
Restricted Cash 47 R13.htm
Property and Equipment 48 R14.htm
Accrued Expenses 49 R15.htm
Indebtedness 50 R16.htm
Commitments and Contingencies 51 R17.htm
Convertible Preferred Stock 52 R18.htm
Stock-Based Payments 53 R19.htm
Related Party Transactions 54 R20.htm
Income Taxes 55 R21.htm
Research Agreement 56 R22.htm
Defined Contribution Plan 57 R23.htm
Subsequent Events 58 R24.htm
Selected Quarterly Financial Data (unaudited) 59 R25.htm
Summary of Significant Accounting Policies (Policies) 60 R26.htm
Summary of Significant Accounting Policies (Tables) 61 R27.htm
Cash Equivalents and Marketable Securities (Tables) 62 R28.htm
Fair Value Measurements (Tables) 63 R29.htm
Property and Equipment (Tables) 64 R30.htm
Accrued Expenses (Tables) 65 R31.htm
Indebtedness (Tables) 66 R32.htm
Commitments and Contingencies (Tables) 67 R33.htm
Stock-Based Payments (Tables) 68 R34.htm
Income Taxes (Tables) 69 R35.htm
Selected Quarterly Financial Data (unaudited) (Tables) 70 R36.htm
Nature of Business (Details) 71 R37.htm
Summary of Significant Accounting Policies - Basis of Presentation (Details) 72 R38.htm
Summary of Significant Accounting Policies - Segment Information and Other Long Term Assets (Details) 73 R39.htm
Summary of Significant Accounting Policies - Property and Equipment, Impairment (Details) 74 R40.htm
Summary of Significant Accounting Policies - Net Loss per Share (Details) 75 R41.htm
Summary of Significant Accounting Policies - Recent Accounting Pronouncements (Details) 76 R42.htm
Cash Equivalents and Marketable Securities (Details) 77 R43.htm
Fair Value Measurements (Details) 78 R44.htm
Restricted Cash (Details) 79 R45.htm
Property and Equipment (Details) 80 R46.htm
Accrued Expenses (Details) 81 R47.htm
Indebtedness (Details) 82 R48.htm
Commitments and Contingencies - Operating Leases (Details) 83 R49.htm
Commitments and Contingencies - License Agreements (Details) 84 R50.htm
Convertible Preferred Stock - (Details) 85 R51.htm
Stock-Based Payments - 2016 Stock Incentive Plan (Details) 86 R52.htm
Stock-Based Payments - 2016 Employee Stock Purchase Plan (Details) 87 R53.htm
Stock-Based Payments - Stock Options (Details) 88 R54.htm
Stock-Based Payments - Restricted Common Stock (Details) 89 R55.htm
Stock-Based Payments - Weighted-Average Assumptions to Estimate Fair Value of Stock Options (Details) 90 R56.htm
Stock-Based Payments - Stock-Based Compensation Expense (Details) 91 R57.htm
Related Party Transactions - (Details) 92 R58.htm
Income Taxes - Reconciliation - (Details) 93 R59.htm
Income Taxes - Deferred tax assets and liabilities (Details) 94 R60.htm
Income Taxes - NOL carryforwards (Details) 95 R61.htm
Income Taxes - Valuation Allowance (Details) 96 R62.htm
Income Taxes - Tax credit carryforwards (Details) 97 R63.htm
Research Agreement (Details) 98 R64.htm
Defined Contribution Plan - (Details) 99 R65.htm
Subsequent Events - (Details) 100 R66.htm
Selected Quarterly Financial Data (unaudited) - (Details) 101 R67.htm
Type Filing Company SIC Rel IRS # State of INC FY End Mailing address Former Filing Vals
filer
Syros Pharmaceuticals, Inc.
Cik: 0001556263
620 MEMORIAL DRIVE
SUITE 300
CAMBRIDGE,  MA,  02139
  USA
2834 -
Pharmaceutical Preparations
453772460 USA [ DE ] 1231
620 MEMORIAL DRIVE
SUITE 300
CAMBRIDGE,  MA,  02139
  USA
Aug. 15, 2012LS22, Inc.
form type10-K
act34
file number001-37813
film number17700049